Genelux Corporation to Participate in Fireside Chat at BTIG’s Virtual Biotechnology Conference 2023
02 Août 2023 - 10:00PM
Genelux Corporation (NASDAQ: GNLX), a late clinical-stage
immuno-oncology company, today announced that Thomas Zindrick,
President, CEO and Chairman, will discuss clinical-stage programs,
recent announcements, and upcoming milestones in a fireside chat at
BTIG’s Virtual Biotechnology Conference 2023.
The conversation with Kaveri Pohlman, PhD,
Director and BTIG Biotechnology Analyst, is scheduled to begin at
4:00 p.m. ET on Tuesday, August 8, 2023.
About Genelux
CorporationGenelux is a late clinical-stage
biopharmaceutical company focused on developing a pipeline of
next-generation oncolytic immunotherapies for patients suffering
from aggressive and/or difficult-to-treat solid tumor types. The
Company's most advanced product candidate, Olvi-Vec (olvimulogene
nanivacirepvec), is a proprietary, modified strain of the vaccinia
virus (VACV), a stable DNA virus with a large engineering capacity.
Olvi-Vec currently is being evaluated in OnPrime/GOG-3076, a
multi-center, randomized, open-label Phase 3 registrational trial
evaluating the efficacy and safety of Olvi-Vec in patients with
platinum-resistant/refractory ovarian cancer. The core of Genelux'
discovery and development efforts revolves around the Company's
proprietary CHOICE™ platform from which the Company has developed
an extensive library of isolated and engineered oncolytic vaccinia
virus immunotherapeutic product candidates, including Olvi-Vec. For
more information, please visit www.genelux.com and follow us on
Twitter @Genelux_Corp and on LinkedIn.
Investor and Media Contacts
Ankit Bhargava, MDAllele Communications,
LLCgenelux@allelecomms.com
Source: Genelux Corporation
Genelux (NASDAQ:GNLX)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Genelux (NASDAQ:GNLX)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024